Abstract: A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described.

Abstract: A composition for use in the treatment or prophylaxis of conditions mediated by endothelial function in mammals is provided. The composition includes a milk protein hydrolysate generated by treating milk or milk whey protein with a proteolytic enzyme having subtilisin or subtilisin-like activity and/or glutamyl endopeptidase or glutamyl endopeptidase-like activity. The composition is useful in the management of vascular conditions.

Abstract: A method for screening, diagnosis or prognosis of sudden death in heart failure in a mammalian subject, for determining sudden death in heart failure in a mammalian subject, for identifying a mammalian subject at risk of sudden death in heart failure, or for monitoring the effect of therapy administered to a mammalian subject at experiencing imminent sudden death in heart failure included measuring the level of C-reactive protein (CRP), myeloperoxidase (MPO), neutrophil count, white blood cell count and BNP in a sample of bodily fluid from the mammalian subject. Methods for monitoring the cardiac health of a mammalian subject are further included. Kits and devices for carrying out such methods are also provided.